Jonsson Comprehensive Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Jonsson Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count).

321 total trials 61 currently recruiting 164 completed early-phase tilt top decile by trial count

Jonsson Comprehensive Cancer Center: 321 sponsored US clinical trials, 61 recruiting.

Jonsson Comprehensive Cancer Center sponsors 321 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 164 completed. 13 of these trials are in Phase 3-4 (later-stage) and 206 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Carcinoma, with 10 trials.

Top-decile sponsor footprint

Jonsson Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 41/100

164 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

321 total, page 5 of 7

COMPLETED

Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients

NCT01051609
COMPLETED Phase 2

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT01149850
COMPLETED NA

Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways

NCT01051037
COMPLETED

Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer

NCT01059513
TERMINATED Phase 2

Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)

NCT01029925
COMPLETED Phase 2

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

NCT00910650
COMPLETED NA

Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men

NCT00955591
COMPLETED Phase 1

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00601094
COMPLETED NA

A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy

NCT00719030
COMPLETED Phase 1

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00104767
COMPLETED Phase 1

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

NCT01005472
TERMINATED Phase 2

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

NCT00880542
COMPLETED

The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases

NCT01180868
COMPLETED NA

Patient-Directed Lifestyle Change and Health Promotion Program or Usual Care in Low-Income, Uninsured Participants in Los Angeles County, California

NCT00521209
COMPLETED NA

Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors

NCT00646633
COMPLETED

The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

NCT01180907
COMPLETED NA

Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery

NCT00685516
TERMINATED Phase 2

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

NCT00612066
TERMINATED Phase 1

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

NCT00234000
COMPLETED Phase 2

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

NCT00471887
TERMINATED Phase 2

Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

NCT00427427
TERMINATED Phase 2

Rosiglitazone in Treating Patients With Pituitary Tumors

NCT00616642
COMPLETED Phase 1

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

NCT00509431
COMPLETED Phase 1

Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy

NCT00790595
COMPLETED Phase 2

Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT01013285
COMPLETED

Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone

NCT00351728
COMPLETED Phase 1

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
COMPLETED Phase 2

Bortezomib in Treating Patients With Metastatic Kidney Cancer

NCT00276614
COMPLETED NA

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma

NCT00335751
COMPLETED Phase 1

Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00345826
COMPLETED Phase 2

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

NCT00255749
COMPLETED NA

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

NCT00433407
TERMINATED Phase 1

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

NCT00093704
TERMINATED Phase 1

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NCT00098917
TERMINATED Phase 2

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

NCT00112749
COMPLETED

Cytogenetic Study of Ocular Melanoma

NCT00344799
COMPLETED Phase 1

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

NCT00107185
COMPLETED Phase 2

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

NCT00107159
COMPLETED Phase 2

Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00138164
COMPLETED

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

NCT00450567
COMPLETED Phase 2

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00096239
COMPLETED NA

Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer

NCT00060086
COMPLETED Phase 3

Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT00112983
COMPLETED Phase 1

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

NCT00100997
COMPLETED NA

Increasing Colorectal Cancer Screening Among Filipino Americans

NCT00742729
COMPLETED Phase 1

BMS-599626 in Treating Patients With Metastatic Solid Tumors

NCT00093730
COMPLETED Phase 2

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00093769
COMPLETED Phase 2

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

NCT00182637
COMPLETED Phase 1

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

NCT00084747
TERMINATED NA

Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

NCT00444223
← Previous Page 5 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 106
Phase 2 100
Phase 3 12
Phase 4 1

Therapeutic Areas

Prostate Carcinoma 10
Prostate Adenocarcinoma 9
Recurrent Prostate Carcinoma 7
Stage IVB Prostate Cancer AJCC v8 6
Prostate Cancer 6
Brain and Central Nervous System Tumors 4
Colorectal Carcinoma 4
Stage IVA Prostate Cancer AJCC v8 4
Stage II Prostate Cancer AJCC v8 4
Stage III Prostate Cancer AJCC v8 4

What is open in the Jonsson Comprehensive Cancer Center pipeline

61 recruiting of 321 indexed (19% open); 164 completed (51%).

Phase mix: 13 late (III/IV) vs 206 early (I/II) (early-phase heavy).

Top condition: Prostate Carcinoma (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Jonsson Comprehensive Cancer Center: open-pipeline peers nationwide

Peers matched on 321 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20% Total trials Recruiting share Jonsson Comprehensive Cancer CenterRush University Medical CenterUniversity of ArkansasAllerganGenentechMemorialCare Health SystemUniversity of North Texas Health Science CenterUniversity of Wisconsin, MilwaukeeVerastem
Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 321 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Jonsson Comprehensive Cancer Center page

321 registered trials is a research-attention snapshot, not an endorsement of Jonsson Comprehensive Cancer Center or any single study.

  • 61 of Jonsson Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Carcinoma is the condition Jonsson Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jonsson Comprehensive Cancer Center pipeline card: 321 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.